Literature DB >> 18680765

Role of nuclear bodies in apoptosis signalling.

Eva Krieghoff-Henning1, Thomas G Hofmann.   

Abstract

Promyelocytic leukemia nuclear bodies (PML NBs) are dynamic macromolecular multiprotein complexes that recruit and release a plethora of proteins. A considerable number of PML NB components play vital roles in apoptosis, senescence regulation and tumour suppression. The molecular basis by which PML NBs control these cellular responses is still just beginning to be understood. In addition to PML itself, numerous further tumour suppressors including transcriptional regulator p53, acetyl transferase CBP (CREB binding protein) and protein kinase HIPK2 (homeodomain interacting protein kinase 2) are recruited to PML NBs in response to genotoxic stress or oncogenic transformation and drive the senescence and apoptosis response by regulating p53 activity. Moreover, in response to death-receptor activation, PML NBs may act as nuclear depots that release apoptotic factors, such as the FLASH (FLICE-associated huge) protein, to amplify the death signal. PML NBs are also associated with other nuclear domains including Cajal bodies and nucleoli and share apoptotic regulators with these domains, implying crosstalk between NBs in apoptosis regulation. In conclusion, PML NBs appear to regulate cell death decisions through different, pathway-specific molecular mechanisms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18680765     DOI: 10.1016/j.bbamcr.2008.07.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  34 in total

Review 1.  Role of the nucleus in apoptosis: signaling and execution.

Authors:  Evgeniia A Prokhorova; Alexey V Zamaraev; Gelina S Kopeina; Boris Zhivotovsky; Inna N Lavrik
Journal:  Cell Mol Life Sci       Date:  2015-09-07       Impact factor: 9.261

Review 2.  The DNA damage-induced cell death response: a roadmap to kill cancer cells.

Authors:  Sonja Matt; Thomas G Hofmann
Journal:  Cell Mol Life Sci       Date:  2016-01-20       Impact factor: 9.261

Review 3.  Hepatitis C-associated liver carcinogenesis: role of PML nuclear bodies.

Authors:  Kerstin Herzer; Guido Gerken; Thomas G Hofmann
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 4.  Physiology of the read-write genome.

Authors:  James A Shapiro
Journal:  J Physiol       Date:  2014-06-01       Impact factor: 5.182

5.  The Cullin 3 substrate adaptor KLHL20 mediates DAPK ubiquitination to control interferon responses.

Authors:  Yu-Ru Lee; Wei-Chien Yuan; Hsuan-Chung Ho; Chun-Hau Chen; Hsiu-Ming Shih; Ruey-Hwa Chen
Journal:  EMBO J       Date:  2010-04-13       Impact factor: 11.598

6.  The proteins of intra-nuclear bodies: a data-driven analysis of sequence, interaction and expression.

Authors:  Nurul Mohamad; Mikael Bodén
Journal:  BMC Syst Biol       Date:  2010-04-13

7.  Phosphoproteomics profiling of human skin fibroblast cells reveals pathways and proteins affected by low doses of ionizing radiation.

Authors:  Feng Yang; Katrina M Waters; John H Miller; Marina A Gritsenko; Rui Zhao; Xiuxia Du; Eric A Livesay; Samuel O Purvine; Matthew E Monroe; Yingchun Wang; David G Camp; Richard D Smith; David L Stenoien
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

8.  Src kinase modulates the apoptotic p53 pathway by altering HIPK2 localization.

Authors:  Tilman Polonio-Vallon; Joanna Kirkpatrick; Jeroen Krijgsveld; Thomas G Hofmann
Journal:  Cell Cycle       Date:  2013-10-25       Impact factor: 4.534

9.  Influence of ND10 components on epigenetic determinants of early KSHV latency establishment.

Authors:  Thomas Günther; Sabrina Schreiner; Thomas Dobner; Uwe Tessmer; Adam Grundhoff
Journal:  PLoS Pathog       Date:  2014-07-17       Impact factor: 6.823

Review 10.  A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics.

Authors:  Ellen Van Damme; Kris Laukens; Thanh Hai Dang; Xaveer Van Ostade
Journal:  Int J Biol Sci       Date:  2010-01-12       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.